| 1 | Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis | 4.2 | 4 | Citations (PDF) |
| 2 | Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set | 12.4 | 1 | Citations (PDF) |
| 3 | Patient research partner involvement in rheumatology research: a systematic literature review informing the 2023 updated EULAR recommendations for the involvement of patient research partners | 12.4 | 6 | Citations (PDF) |
| 4 | GRAPPA 2023 Patient Research Partner (PRP) Network Update: Enhancing PRP Involvement Within GRAPPA | 2.4 | 2 | Citations (PDF) |
| 5 | How to Involve Patients in GRAPPA Research as Partners | 2.4 | 1 | Citations (PDF) |
| 6 | Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study | 4.2 | 14 | Citations (PDF) |
| 7 | Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis | 3.7 | 8 | Citations (PDF) |
| 8 | Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohorts | 4.2 | 3 | Citations (PDF) |
| 9 | Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence | 2.2 | 21 | Citations (PDF) |
| 10 | Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals | 1.9 | 11 | Citations (PDF) |
| 11 | Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact | 1.9 | 2 | Citations (PDF) |
| 12 | Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries | 4.2 | 9 | Citations (PDF) |
| 13 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 | 26.0 | 488 | Citations (PDF) |
| 14 | Unmet need for patient involvement in rheumatology registries and observational studies: a mixed methods study | 4.2 | 5 | Citations (PDF) |
| 15 | Consideration of health literacy in patient information: a mixed-methods study of COVID-19 crisis communication in Dutch rheumatology | 2.2 | 4 | Citations (PDF) |
| 16 | Patient involvement in basic rheumatology research at Nijmegen: a three year’s responsive evaluation of added value, pitfalls and conditions for success | 2.2 | 12 | Citations (PDF) |
| 17 | Comparing the Patient‐Reported Physical Function Outcome Measures in a Real‐Life International Cohort of Patients With Psoriatic Arthritis | 3.0 | 12 | Citations (PDF) |
| 18 | Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals? | 3.0 | 38 | Citations (PDF) |
| 19 | Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group | 12.4 | 8 | Citations (PDF) |
| 20 | Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients | 4.2 | 15 | Citations (PDF) |
| 21 | What influences patients’ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study | 1.9 | 7 | Citations (PDF) |
| 22 | Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study | 2.0 | 18 | Citations (PDF) |
| 23 | Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial | 12.4 | 88 | Citations (PDF) |
| 24 | Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study | 2.4 | 3 | Citations (PDF) |
| 25 | OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study | 4.0 | 10 | Citations (PDF) |
| 26 | Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach | 4.0 | 18 | Citations (PDF) |
| 27 | Researchers’ perspectives on methodological challenges and outcomes selection in interventional studies targeting medication adherence in rheumatic diseases: an OMERACT-adherence study | 2.2 | 3 | Citations (PDF) |
| 28 | Psoriatic arthritis | 50.8 | 294 | Citations (PDF) |
| 29 | Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report | 4.0 | 10 | Citations (PDF) |
| 30 | Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging | 4.0 | 21 | Citations (PDF) |
| 31 | Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology | 4.2 | 6 | Citations (PDF) |
| 32 | Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique | 3.0 | 25 | Citations (PDF) |
| 33 | Determinants of Patient‐Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association WithSex in 458 Patients From Fourteen Countries | 3.0 | 49 | Citations (PDF) |
| 34 | Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties | 0.9 | 7 | Citations (PDF) |
| 35 | Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review | 2.4 | 20 | Citations (PDF) |
| 36 | Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research | 4.2 | 53 | Citations (PDF) |
| 37 | EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries | 12.4 | 17 | Citations (PDF) |
| 38 | Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis | 12.4 | 113 | Citations (PDF) |
| 39 | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis | 12.4 | 241 | Citations (PDF) |
| 40 | Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group | 12.4 | 3 | Citations (PDF) |
| 41 | Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis | 12.4 | 229 | Citations (PDF) |
| 42 | Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal? | 12.4 | 54 | Citations (PDF) |
| 43 | Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries | 2.3 | 18 | Citations (PDF) |
| 44 | Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries | 12.4 | 10 | Citations (PDF) |
| 45 | Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group | 2.4 | 5 | Citations (PDF) |
| 46 | Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative | 2.4 | 11 | Citations (PDF) |
| 47 | Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology | 2.4 | 82 | Citations (PDF) |
| 48 | Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials | 2.4 | 9 | Citations (PDF) |
| 49 | “Be an ambassador for change that you would like to see”: a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease | 3.3 | 15 | Citations (PDF) |
| 50 | Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) | 3.2 | 67 | Citations (PDF) |
| 51 | Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017 | 2.4 | 29 | Citations (PDF) |
| 52 | Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018 | 2.4 | 6 | Citations (PDF) |
| 53 | OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions | 2.4 | 18 | Citations (PDF) |
| 54 | Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report | 2.4 | 57 | Citations (PDF) |
| 55 | Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development | 2.4 | 32 | Citations (PDF) |
| 56 | OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies | 2.4 | 124 | Citations (PDF) |
| 57 | Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology | 2.4 | 87 | Citations (PDF) |
| 58 | PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials | 2.4 | 53 | Citations (PDF) |
| 59 | Unique role of rheumatology in establishing collaborative relationships in research. Past, present and future of patient engagement | 12.4 | 22 | Citations (PDF) |
| 60 | Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries | 12.4 | 70 | Citations (PDF) |
| 61 | The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis | 2.4 | 150 | Citations (PDF) |
| 62 | International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group | 3.0 | 69 | Citations (PDF) |
| 63 | The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual
Meeting: Report and Plan for Completing the Core Outcome Measurement
Set | 2.4 | 14 | Citations (PDF) |
| 64 | Proceedings of the 2018 GRAPPA Collaborative Research Network
Meeting | 2.4 | 7 | Citations (PDF) |
| 65 | Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients | 2.5 | 15 | Citations (PDF) |
| 66 | Preparing researchers for patient and public involvement in scientific research: Development of a hands‐on learning approach through action research | 3.0 | 48 | Citations (PDF) |
| 67 | Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice‐Based Call for a Paradigm Change | 3.0 | 97 | Citations (PDF) |
| 68 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force | 12.4 | 582 | Citations (PDF) |
| 69 | Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta‐Epidemiologic Study | 3.0 | 5 | Citations (PDF) |
| 70 | A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative | 4.0 | 62 | Citations (PDF) |
| 71 | Development of a standard form for assessing research grant applications from the perspective of patients | 2.5 | 9 | Citations (PDF) |
| 72 | Content and Face Validity and Feasibility of 5 Candidate Instruments for
Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set
Workshop at the GRAPPA 2017 Annual Meeting | 2.4 | 11 | Citations (PDF) |
| 73 | Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016 | 2.4 | 120 | Citations (PDF) |
| 74 | International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials | 12.4 | 238 | Citations (PDF) |
| 75 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | 12.4 | 3,466 | Citations (PDF) |
| 76 | Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group | 2.4 | 48 | Citations (PDF) |
| 77 | Emerging Guidelines for Patient Engagement in Research | 2.0 | 182 | Citations (PDF) |
| 78 | Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients | 1.9 | 76 | Citations (PDF) |
| 79 | Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016 | 2.4 | 16 | Citations (PDF) |
| 80 | Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting | 2.4 | 25 | Citations (PDF) |
| 81 | “They Are Talking About Me, but Not with Me”: A Focus Group Study to Explore the Patient Perspective on Interprofessional Team Meetings in Primary Care | 2.4 | 30 | Citations (PDF) |
| 82 | Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set | 4.2 | 39 | Citations (PDF) |
| 83 | Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative | 12.4 | 223 | Citations (PDF) |
| 84 | Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force | 12.4 | 299 | Citations (PDF) |
| 85 | Fatigue in psoriatic arthritis – a cross-sectional study of 246 patients from 13 countries | 2.3 | 56 | Citations (PDF) |
| 86 | Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis | 12.4 | 103 | Citations (PDF) |
| 87 | Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP | 2.4 | 52 | Citations (PDF) |
| 88 | Successful Stepwise Development of Patient Research Partnership: 14 Years’ Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT) | 2.4 | 51 | Citations (PDF) |
| 89 | 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations | 12.4 | 261 | Citations (PDF) |
| 90 | Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making | 2.4 | 22 | Citations (PDF) |
| 91 | Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting | 2.4 | 11 | Citations (PDF) |
| 92 | Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures | 2.4 | 27 | Citations (PDF) |
| 93 | Updating the OMERACT Filter: Implications for Patient-reported Outcomes | 2.4 | 55 | Citations (PDF) |
| 94 | A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative | 12.4 | 379 | Citations (PDF) |
| 95 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | 12.4 | 1,744 | Citations (PDF) |
| 96 | Patient Involvement in Outcome Measures for Psoriatic Arthritis | 4.4 | 39 | Citations (PDF) |
| 97 | Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project | 12.4 | 9 | Citations (PDF) |
| 98 | Patient perspective in outcome measures developed by OMERACT | 0.3 | 9 | Citations (PDF) |
| 99 | Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences | 2.0 | 166 | Citations (PDF) |
| 100 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions | 12.4 | 108 | Citations (PDF) |
| 101 | Facilitating and inhibiting factors for long-term involvement of patients at outcome conferences—lessons learnt from a decade of collaboration in OMERACT: a qualitative study | 2.0 | 30 | Citations (PDF) |
| 102 | American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials | 12.4 | 714 | Citations (PDF) |
| 103 | Treating rheumatoid arthritis to target: recommendations of an international task force | 12.4 | 1,859 | Citations (PDF) |
| 104 | Patients and professionals as research partners: Challenges, practicalities, and benefits | 6.0 | 233 | Citations (PDF) |
| 105 | Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group | 2.4 | 4 | Citations (PDF) |
| 106 | Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting | 2.4 | 1 | Citations (PDF) |
| 107 | EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis | 12.4 | 76 | Citations (PDF) |
| 108 | Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting | 2.4 | 2 | Citations (PDF) |
